Ka

Kartos

Redwood City CAFounded 201840 employees
Private CapbiotechPrivateHematology
Platform: Myelofibrosis
Market Cap
N/A
All Drugs
4
Clinical Trials
7
Failed / Terminated
2
FDA Approved
1
Drug Pipeline (4 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
KAR-5490KAR-5490Phase 11Bispecific AbRETKIF18AiEpilepsyRSV
KAR-9558KAR-9558Approved3Fusion ProteinUSP1MALT1iHS
KAR-2338KAR-2338Preclinical1PeptideDLL3PCSK9iCRC
KAR-4449KAR-4449Phase 22RadioligandMETCGRPantMCLBreast Ca
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (7)
2026-01-03
KAR-4449 Ph2 Data
Breast Ca
Past
2026-10-05
KAR-9558 Ph3 Readout
HS
Ph3 Readout
2026-12-17
KAR-9558 Ph3 Readout
HS
Ph3 Readout
2027-02-27
KAR-2338 Interim
CRC
Interim
2030-10-19
KAR-5490 Interim
Epilepsy
Interim
2031-03-10
KAR-9558 Ph3 Readout
HS
Ph3 Readout
2031-11-02
KAR-4449 Ph2 Data
Breast Ca
Ph2 Data